home / stock / clsd / clsd quote
Last: | $0.833 |
---|---|
Change Percent: | 0.08% |
Open: | $0.841 |
Close: | $0.833 |
High: | $0.8698 |
Low: | $0.8249 |
Volume: | 43,485 |
Last Trade Date Time: | 04/28/2025 03:38:25 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.833 | $0.841 | $0.833 | $0.8698 | $0.8249 | 43,485 | 04-28-2025 |
$0.8417 | $0.85 | $0.8417 | $0.8981 | $0.8044 | 71,330 | 04-25-2025 |
$0.8485 | $0.8168 | $0.8485 | $0.8499 | $0.8001 | 101,674 | 04-24-2025 |
$0.7955 | $0.8 | $0.7955 | $0.835 | $0.7863 | 254,890 | 04-23-2025 |
$0.8 | $0.848024 | $0.8 | $0.848024 | $0.7838 | 72,191 | 04-22-2025 |
$0.8 | $0.85 | $0.8 | $0.85 | $0.7862 | 188,012 | 04-21-2025 |
$0.86 | $0.87 | $0.86 | $0.9285 | $0.821 | 266,974 | 04-18-2025 |
$0.86 | $0.87 | $0.86 | $0.9285 | $0.821 | 266,974 | 04-17-2025 |
$0.8698 | $0.82 | $0.8698 | $0.8801 | $0.813 | 139,277 | 04-16-2025 |
$0.8218 | $0.8 | $0.8218 | $0.8349 | $0.8 | 62,249 | 04-15-2025 |
$0.8001 | $0.77 | $0.8001 | $0.8128 | $0.76 | 196,172 | 04-14-2025 |
$0.7649 | $0.75 | $0.7649 | $0.779 | $0.7409 | 231,422 | 04-11-2025 |
$0.7491 | $0.78 | $0.7491 | $0.79 | $0.71 | 200,694 | 04-10-2025 |
$0.7668 | $0.8 | $0.7668 | $0.80525 | $0.7001 | 324,432 | 04-09-2025 |
$0.8191 | $0.8875 | $0.8191 | $0.94 | $0.8014 | 242,769 | 04-08-2025 |
$0.8453 | $0.86 | $0.8453 | $0.94 | $0.8223 | 363,649 | 04-07-2025 |
$0.861 | $0.8611 | $0.861 | $0.9 | $0.8446 | 156,014 | 04-04-2025 |
$0.8998 | $0.9 | $0.8998 | $0.94 | $0.8857 | 118,672 | 04-03-2025 |
$0.93 | $0.92 | $0.93 | $0.9399 | $0.9007 | 62,279 | 04-02-2025 |
$0.9076 | $0.9 | $0.9076 | $0.9599 | $0.9 | 112,358 | 04-01-2025 |
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
0.08% G/L:
$0.833 Last:
43,485 Volume:
$0.841 Open:
$0.833 Close:
Clearside Biomedical Inc. Website:
ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that George Lasezkay, PharmD, JD, Pr...
- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner’s New Drug Application for ARCATUS ® (XIPERE ® ) for Uveitic Macular Edema Accepted for Regulatory Review in China - -...
HG Holdings Inc (STLY) is expected to report for quarter end 2024-12-31 Savara Inc. (SVRA) is expected to report $-0.11 for Q4 2024 Reborn Coffee Inc. (REBN) is expected to report for quarter end 2024-12-31 VSee Health Inc. (VSEE) is expected to report for Q4 2024 IceCure Medical ...